PT  - JOURNAL ARTICLE
AU  - YONG SIK YOON
AU  - CHAN WOOK KIM
AU  - SEON AE ROH
AU  - DONG HYUNG CHO
AU  - GYU PYO KIM
AU  - YONG SANG HONG
AU  - TAE WON KIM
AU  - MOON BO KIM
AU  - JIN CHEON KIM
TI  - Applicability of Histoculture Drug Response Assays in Colorectal Cancer Chemotherapy
DP  - 2012 Aug 01
TA  - Anticancer Research
PG  - 3581--3586
VI  - 32
IP  - 8
4099  - http://ar.iiarjournals.org/content/32/8/3581.short
4100  - http://ar.iiarjournals.org/content/32/8/3581.full
SO  - Anticancer Res2012 Aug 01; 32
AB  - Aim: The present study, using the histoculture drug response assay (HDRA) compared chemosensitivity with the clinical response of a treatment regime in patients with advanced colorectal cancer (CRC). Patients and Methods: A total of 324 patients with primary CRC were prospectively enrolled. HDRAs were performed using seven combinations of anticancer drugs, including 5-fluorouracil with leucovorin (FL), FL with oxaliplatin (FOLFOX), irinotecan (FOLFIRI), and their combinations with bevacizumab and cetuximab. Results: Among 324 HDRA results, tumor inhibition rates of regimes using FOLFOX (34.2-39.2%) were higher than those using FOLFIRI (24.2-32.7%, p<0.001). Out of 86 evaluated chemotherapeutic regimes, the correlation rate of HDRA to the clinical effect of chemotherapy was calculated to be 66.3% (57/86), with a 72.7% (40/55) sensitivity and a 54.7% (17/31) specificity. Conclusion: HDRA might be a feasible and useful technique for predicting therapy efficacy and selecting the appropriate anticancer regime for individual patients, notwithstanding its low accuracy.